19,248 Shares in GSK plc (NYSE:GSK) Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB purchased a new position in shares of GSK plc (NYSE:GSK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,248 shares of the pharmaceutical company’s stock, valued at approximately $787,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of GSK. FMR LLC increased its position in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Primecap Management Co. CA increased its position in shares of GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after acquiring an additional 342,365 shares in the last quarter. Provident Trust Co. increased its position in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock worth $161,623,000 after acquiring an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its position in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Down 0.6 %

NYSE GSK opened at $33.95 on Monday. GSK plc has a 12 month low of $32.83 and a 12 month high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a market capitalization of $70.36 billion, a price-to-earnings ratio of 22.05, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. The company’s fifty day moving average price is $36.18 and its two-hundred day moving average price is $39.21.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a yield of 4.63%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio is 99.35%.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and decreased their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Barclays upgraded shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.